Can-Fite BioPharma (CANF) Tops Q3 EPS by 8c

Can-Fite BioPharma (NYSE: CANF) reported Q3 EPS of ($0.01), $0.08 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $613 thousand versus the consensus estimate of $300 thousand.

For earnings history and earnings-related data on Can-Fite BioPharma (CANF) click here.

You May Also Be Interested In

• Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
• WM (WM) Tops Q1 EPS by 25c
• ATN International (ATNI) Misses Q1 EPS by 46c ; Offers Guidance